OC
ALNY icon

Oppenheimer & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Oppenheimer & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-966
Closed -$384K – 1688
2025
Q4 		$384K Sell
966
-750
-44% -$332K 0.01% 1174
2025
Q3 		$782K Hold
1,716
– – 0.01% 1012
2025
Q2 		$560K Hold
1,716
– – 0.01% 1097
2025
Q1 		$463K Hold
1,716
– – 0.01% 1097
2024
Q4 		$404K Sell
1,716
-190
-10% -$50K 0.01% 1149
2024
Q3 		$524K Buy
1,906
+190
+11% +$49.5K 0.01% 1018
2024
Q2 		$417K Hold
1,716
– – 0.01% 1066
2024
Q1 		$256K Sell
1,716
-2,663
-61% -$444K ﹤0.01% 1239
2023
Q4 		$838K Sell
4,379
-140
-3% -$23.8K 0.02% 770
2023
Q3 		$800K Buy
4,519
+93
+2% +$17.7K 0.02% 751
2023
Q2 		$841K Buy
4,426
+149
+3% +$29.5K 0.02% 773
2023
Q1 		$857K Sell
4,277
-47
-1% -$9.88K 0.02% 744
2022
Q4 		$1.03M Buy
4,324
+31
+0.7% +$6.61K 0.02% 671
2022
Q3 		$859K Sell
4,293
-763
-15% -$146K 0.02% 706
2022
Q2 		$738K Buy
5,056
+44
+0.9% +$6.24K 0.02% 790
2022
Q1 		$819K Buy
5,012
+2,169
+76% +$330K 0.01% 819
2021
Q4 		$482K Buy
2,843
+504
+22% +$93.7K 0.01% 1044
2021
Q3 		$441K Hold
2,339
– – 0.01% 1063
2021
Q2 		$397K Hold
2,339
– – 0.01% 1121
2021
Q1 		$331K Hold
2,339
– – 0.01% 1126
2020
Q4 		$304K Buy
2,339
+39
+2% +$5.21K 0.01% 1075
2020
Q3 		$335K Hold
2,300
– – 0.01% 943
2020
Q2 		$341K Buy
+2,300
New +$310K 0.01% 926

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oppenheimer & Co's ALNY Position: Q1 2026 in Review

Oppenheimer & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 966 shares — an estimated $384K sold.

Oppenheimer & Co first reported a position in ALNY in Q2 2020 and held it in 23 quarters. The position peaked at $1.03M in Q4 2022. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Oppenheimer & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Oppenheimer & Co sold 966 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $384K.
  • Oppenheimer & Co first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 23 quarters.
  • Oppenheimer & Co's Alnylam Pharmaceuticals position peaked at $1.03M in Q4 2022.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.